Clinical Trial Search

Primary: Change in Migraine Characteristics — 43; 2; 17 Participants

Primary: The Number of Subjects With a Numeric Rating Scale Score (NRS) of Zero at Two Hours. — 5; 12 participants — p=0.03

Primary: Proportion of People With "Severe" Scores on the Migraine Disability Assessment — 77.4; 89.7; 58.1; 75.9 percentage of participants — p=.027

Primary: Migraine Functional Impairment as Measured by Score on the Headache Impact Test 6 (HIT6) Scale — 59; 56 units on a scale

Primary: Percentage of Participants With Episodic Migraine (EM) or Chronic Migraine (CM) — 91.2; 8.8 percentage of participants

Primary: Pain Relief at 2 Hours During the First Migraine Attack Period — 246; 30; 74; 52 participants

Primary: Headache Days — 23.64; 24.33 Days — p=0.83

Primary: Change in Number of Monthly Migraine Headache Days — -3.5; -1.1 migraine days

Primary: Change in Mean Visual Analog Scale (VAS) Score — -2.3; -2.7 cm

Primary: Change in MMD (Monthly Migraine Days) — -3.04; -2.14 migraine days per month

Primary: Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6 — 5.9; 6.2; 6.6; -0.9 Migraine attacks — p=0.1646

Primary: Change in the Number of Days With Migraine (in Migraine Frequency) — 9.9; 12.4; 11.8; 6.3 days/month — p=0.001

Primary: Treatment Session Adherence Rate — 7.88; 8 Number of sessions attended

Primary: Adherence to Acute Migraine Management Strategies: Treat Early — 0; 2 Participants

Primary: Frequency of Migraine Attacks (Number of Days Per Month) — 8.45; 5.65 Number of migraine per months — p=0.012

Primary: Percentage of Participants With Reduction of Migraine Headache at 2 Hours Post Treatment — 66; 40 Participants

Primary: Primary Efficacy Endpoint - Percentage of Subjects With a 50% Reduction From Baseline in the Monthly Number of Migraine Attacks at 12 Months. — 32; 38 percentage of…

Primary: Migraine Frequency at 12 Weeks — -5.5; -3.9 days

Primary: Number of Participants With Adverse Events — 110; 85; 79 Participants

Primary: Number of Headache Days Per Month — 10.6; 10.9 days per month — p=0.63

Primary: Migraine Headache Days — 7.12; 6.92; 5.53; 4.79 Days

Primary: Headache Days as Self-reported by Participants — 3.0; 3.3 days

Primary: Number of Subjects With Pain Relief at 2 Hours From Time of First Dose — 136; 231 participants

Primary: Percentage Decrease in Migraine Episodes — 48; 57; 46 Percentage decrease in migraine episodes — p=0.6207

Primary: Persistent Headache Pain Free at 24 Hours — 26; 19 Participants

Primary: Number of Migraine/Migrainous Days Per 28 Day Period — 3.6; 4.9 days

Primary: Change From Baseline in Number of Migraine Days Per Four Weeks During the Three Months Post Treatment Investigation Duration — -1.5; -1.3 Migraine days/four weeks…

Primary: Pain Intensity Score — 4.7; 4.9; 5.3 scores on a scale

Primary: Proportion of Subjects Reporting Reduction of Migraine Headache Pain at 2 Hours From Treatment Initiation — 30; 22 Participants — p=0.018

Primary: Mean Change From Baseline in the Number of Migraine Headache Days in the Last 28-day Period of the 12-week Treatment Phase — -4.2; -3.0 Migraine headache days